Literature DB >> 33594147

Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment.

Paweł Łaniewski1, Haiyan Cui2, Denise J Roe2, Dana M Chase2,3,4,5,6, Melissa M Herbst-Kralovetz7,8,9.   

Abstract

Emerging evidence suggests that the vaginal microbiota play a role in HPV persistence and cervical neoplasia development and progression. Here we examine a broad range of immune checkpoint proteins in the cervicovaginal microenvironment across cervical carcinogenesis and explore relationships among these key immunoregulatory proteins, the microbiota composition, and genital inflammation. First, we demonstrate that immune checkpoint molecules can be measured in cervicovaginal lavages. Secondly, we identify CD40, CD27, and TIM-3 to specifically discriminate cervical cancer from other groups and CD40, CD28, and TLR2 to positively correlate to genital inflammation. Finally, PD-L1 and LAG-3 levels negatively, whereas TLR2 positively correlate to health-associated Lactobacillus dominance. Overall, our study identifies immune checkpoint signatures associated with cervical neoplasm and illuminates the multifaceted microbiota-host immunity network in the local microenvironment. This study provides a foundation for future mechanistic studies and highlights the utility of cervicovaginal lavage profiling for predicting and monitoring response to cancer therapy.

Year:  2020        PMID: 33594147     DOI: 10.1038/s41698-020-0126-x

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN: 2397-768X


  21 in total

Review 1.  The role of Pap test screening against cervical cancer: a systematic review and meta-analysis.

Authors:  A Meggiolaro; B Unim; L Semyonov; S Miccoli; E Maffongelli; G La Torre
Journal:  Clin Ter       Date:  2016 Jul-Aug

2.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

3.  Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis.

Authors:  Wojciech Kwasniewski; Maria Wolun-Cholewa; Jan Kotarski; Wojciech Warchol; Dorota Kuzma; Anna Kwasniewska; Anna Gozdzicka-Jozefiak
Journal:  Oncol Lett       Date:  2018-09-26       Impact factor: 2.967

4.  Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis.

Authors:  Paweł Łaniewski; Haiyan Cui; Denise J Roe; Dominique Barnes; Alison Goulder; Bradley J Monk; David L Greenspan; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.379

Review 5.  PD-1/PD-L1 Inhibitors in Cervical Cancer.

Authors:  Yuncong Liu; Li Wu; Ruizhan Tong; Feiyue Yang; Limei Yin; Mengqian Li; Liting You; Jianxin Xue; You Lu
Journal:  Front Pharmacol       Date:  2019-02-01       Impact factor: 5.810

6.  Going beyond the individual: how state-level characteristics relate to HPV vaccine rates in the United States.

Authors:  Melissa Franco; Stephanie Mazzucca; Margaret Padek; Ross C Brownson
Journal:  BMC Public Health       Date:  2019-02-28       Impact factor: 3.295

7.  Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.

Authors:  Yi Zheng; Tingting Wang; Xiaoxuan Tu; Yun Huang; Hangyu Zhang; Di Tan; Weiqin Jiang; Shunfeng Cai; Peng Zhao; Ruixue Song; Peilu Li; Nan Qin; Weijia Fang
Journal:  J Immunother Cancer       Date:  2019-07-23       Impact factor: 13.751

8.  Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study.

Authors:  Astride Audirac-Chalifour; Kirvis Torres-Poveda; Margarita Bahena-Román; Juan Téllez-Sosa; Jesús Martínez-Barnetche; Bernardo Cortina-Ceballos; Guillermina López-Estrada; Karina Delgado-Romero; Ana I Burguete-García; David Cantú; Alejandro García-Carrancá; Vicente Madrid-Marina
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

9.  Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity.

Authors:  A Mitra; D A MacIntyre; Y S Lee; A Smith; J R Marchesi; B Lehne; R Bhatia; D Lyons; E Paraskevaidis; J V Li; E Holmes; J K Nicholson; P R Bennett; M Kyrgiou
Journal:  Sci Rep       Date:  2015-11-17       Impact factor: 4.379

10.  Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.

Authors:  Paweł Łaniewski; Dominique Barnes; Alison Goulder; Haiyan Cui; Denise J Roe; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.